DIA

Awards & Advancement

DeHaemer joins CSS as senior enrollment specialist role

Tuesday, January 15, 2013 08:00 AM

Clinical Site Services (CSS), a site performance company that provides solutions to increase the enrollment potential for investigative sites, has appointed Teresa DeHaemer as a senior enrollment specialist.

More... »

ACRP Certification Program - July 31st

ICON appoints Howie as chief marketing officer

Monday, January 14, 2013 11:07 AM

Icon,a global provider of outsourced development services, has named Robert L. Howie, Jr. as its new chief marketing officer. 

More... »

CRF Health – eCOA Forum

Cyberonics names KenKnight as vice president of emerging therapies

Friday, January 11, 2013 12:33 PM

Cyberonics, a medical technology company with core expertise in neuromodulation, has appointed Bruce H. KenKnight, Ph.D., as vice president of Emerging Therapies.

More... »

AtheroNova names Shaw as new clinical affairs officer

Thursday, January 10, 2013 08:00 AM

AtheroNova, a biotech company focused on compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, has appointed Joan E. Shaw, MT (ASCP), SCC as senior director of clinical operations.

More... »

Coronado appoints Weisman as CEO

Wednesday, January 9, 2013 12:08 PM

Coronado Biosciences, a Burlington, Mass.-based biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, has appointed Harlan F. Weisman, M.D., as its new chairman and CEO.

More... »

Ambrx appoints Macartney as CEO

Tuesday, January 8, 2013 08:00 AM

Ambrx, a clinical-stage biopharmaceutical company using an expanded genetic code to create best-in-class biotherapeutics, has appointed Lawson Macartney, Ph.D., DVM, as president and CEO of the company and a member of the board of directors.

More... »

Tim Mayleben named president and CEO of Esperion Therapeutics

Friday, January 4, 2013 01:56 PM

Esperion Therapeutics, a developer of small molecule therapies for the treatment of cardiometabolic disorders, has named Tim Mayleben as the new president and CEO of the company. Roger Newton, Ph.D., FAHA, who is the founder of Esperion and has been serving as its president and CEO, will become executive chairman and chief scientific officer.

More... »

Heffernan and Koch join Lilly’s autoimmune team

Friday, January 4, 2013 01:17 PM

Global pharmaceutical company Eli Lilly has appointed Michael P. Heffernan, M.D., a nationally recognized expert in complex medical dermatology, psoriasis and clinical trials, as a distinguished medical fellow of its autoimmune team. Alisa E. Koch, M.D., a rheumatologist who has won numerous academic awards for her extensive work in rheumatoid arthritis, also joined the team as senior medical fellow.

More... »

CRA receives silver Best in Biz Award for executive team of the year

Wednesday, January 2, 2013 04:01 PM

Clinical Research Advantage (CRA), a service provider based in Tempe, Ariz., received a national honor in this year’s Best in Biz Awards, the only independent business awards program judged by members of the press and industry analysts. CRA received the silver award for executive team of the year.

More... »

Texas Health Resources selects Daniel Varga as CCO

Wednesday, December 19, 2012 12:08 PM

Texas Health Resources, a faith-based, nonprofit health system, has selected Daniel Varga, M.D., as its chief clinical officer (CCO) and senior executive vice president of the health system, effective Jan. 14.

More... »

Almac Clinical Services
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

June 17

New CISCRP study finds patient perceptions of trial participation safety, motives greatly improved

PwC: Volume and value of pharma, diagnostics deals soar in first quarter, as CRO sector waits on sidelines

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

June

Operating environment spurs out-of-the-box ideas
High cost, low success rates drive some sponsors to new monitoring, protocol design, patient-centric initiatives

Private equity interest in CROs could lead to more IPOs
Now flush with cash, many PE investors readying to cash out

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

May

INC Research, PPD, inVentiv named top CROs
Yet most CROs slipping in ability to manage site relationships

R&D cuts by sponsors spur more collaboration, innovation
New strategies share pipeline activity costs

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs